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Objective: We studied how representative cytologically abnormal women (“referral
populations”) are with respect to uncovering differences between human papillo-
mavirus (HPV) assays in the primary screening where most women are cytologically
normal.
Methods: A total of 4997 women were tested with SurePath cytology, and Hybrid
Capture 2 (HC2), cobas, CLART and APTIMA HPV assays. Women with positive test
results were offered a follow-up. For all detected HPV infections and HPV-positive
high-grade cervical intraepithelial neoplasia (≥CIN2), we studied the distributions of
assay-specific signal strengths in the baseline samples as documented by the assays’
automatically generated reports. We calculated the likelihood of test result discordance
as the proportion of HPV-positive samples that were not confirmed by all four assays.
Results: Median signal strengths for HPV infections were weaker in normal than
abnormal cytology (P<.001, adjusted for women’s age, multiple infections and the
reason for taking the sample). For HC2, they were RLU/CO 11.0 (interquartile
range, IQR: 3.3-52.8) vs 124.2 (IQR: 22.8-506.9), respectively; for cobas, Ct 33.5
(IQR: 29.6-37.5) vs 26.9 (IQR: 23.7-31.3), respectively; for APTIMA, S/CO 10.2
(IQR: 5.8-11.3) vs 11.1 (IQR: 9.4-15.5), respectively. Similar patterns were observed
for HPV-positive ≥CIN2. The four HPV assays more frequently returned discordant
test results in normal than in abnormal cytology. Relative frequency of discordance
in detecting HPV infections was 0.39 (95% confidence interval: 0.33-0.48) for
abnormal vs normal cytology.
Conclusions: These data suggest that referral population studies, by not including
sufficient numbers of cytology normal women, underestimate the differences
between HPV assays that would become apparent in primary screening.
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1 | INTRODUCTION
Human papillomavirus (HPV) testing is going to replace cytology in
primary cervical screening. Randomised trials comparing the two
testing modalities in screening showed that women with negative
HPV test results have a lower risk of developing cervical cancer than
women with normal cytology.1
Cervical screening laboratories can now choose between more
than 100 commercially available HPV assays. The randomised trials
were, however, undertaken either with one commercially available
HPV assay, Hybrid Capture 2 (HC2) or with an in-house polymerase
chain reaction (PCR) assay using GP5+/6+ primers. Other, newer,
HPV assays will most likely not be submitted to similarly rigorous
but costly and time-consuming randomised trials. Instead, their accu-
racy of detecting high-grade cervical intraepithelial neoplasia (CIN), a
treatable screening endpoint, has been compared to that of HC2 or
GP5+/6+ in several smaller, predominantly split-sample, studies.2–20
The caveat is that split-sample testing literature is dominated by
studies of referral populations.8,9,11–20 As referral populations typi-
cally include women with abnormal cervical cytology who have a
high risk of ≥CIN2, such studies have several practical advantages
over primary screening studies. The high risk of ≥CIN2 means that
adequately powered referral population studies can be smaller than
adequately powered primary screening studies where the prevalence
of ≥CIN2 is much lower. Furthermore, women with abnormal cytol-
ogy are routinely offered a follow-up, so CIN lesions detected
through abnormal cytology can be traced in routine pathology regis-
trations. In contrast, follow-up of cytology-normal/HPV-positive
women at present necessitates ethical approval and an additional
research infrastructure.
In primary screening, most HPV-positive women have normal
cytology, and the main reason for replacing cytology with HPV test-
ing is to detect also the CIN missed by cytology (ie, the cytologically
normal high-grade CIN). Referral populations, therefore, represent
only selected subgroups of women undergoing primary screening,
and it remains unknown whether they are an adequate substitute
for primary screening populations when HPV assays are being com-
pared.
To shed light on the use of referral populations in studies evalu-
ating HPV assays for primary screening, we compared HPV infec-
tions and ≥CIN2 detected by four commercially available HPV assays
in women with normal vs abnormal cytology.
2 | METHODS
2.1 | Study design
We used data from the Horizon study, the design of which was
described in detail previously.2,21–28 In short, we collected consecu-
tive, routine, SurePath samples from Department of Pathology of
Copenhagen University Hospital Hvidovre in June-August 2011.
Samples from 5034 women were tested with liquid-based cytology
(LBC) and four HPV assays: HC2 (QIAGEN, Gaithersburg, MD, USA),
cobas (Roche, Pleasanton, CA, USA), CLART (Genomica, Madrid,
Spain) and APTIMA (Hologic, San Diego, CA, USA). HC2 was tested
on post-quot cytology material. The residual original material was
diluted 1:1 in SurePath for aliquoting into tubes for cobas, APTIMA,
and CLART testing (Appendix). Cytology was read routinely following
the Bethesda 2001 criteria, blinded to HPV testing outcomes.
Abnormal cytology was defined as atypical squamous cells of unde-
termined significance (ASCUS) or worse.
International Agency for Research on Cancer (IARC) classifies 13
genotypes as high-risk (oncogenic): 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59 and 68. Positive HPV test results on HC2, cobas and
APTIMA were defined as intended by the respective manufacturers,
and signal strengths for positive baseline HPV test results were
determined from the assays’ automatically generated testing docu-
mentation. By design, HC2 detects the 13 high-risk genotypes in
combination, with a signal threshold of ≥1.0 relative light units per
cut-off (RLU/CO). Cobas, on the other hand, detects genotypes 16
and 18 in two separate channels (signal thresholds: critical threshold
(Ct) values ≤40.5 and ≤40.0) and the remaining 11 high-risk plus one
possibly carcinogenic genotype (genotype 66) in combination in a
third channel (signal threshold: ≤40.0 Ct). APTIMA detects the 13
high-risk genotypes plus genotype 66 in combination, with a signal
threshold of ≥0.5 signal to a cut-off (S/CO) value. In these three
assays, low-risk genotypes return a negative test result (except in
cases of cross-reactivity, described in detail previously).28
Among the four studied assays, CLART was the only assay that
allowed individual detection of 35 HPV genotypes (including all 13
defined as high-risk by IARC) and was used in the analysis to discrimi-
nate between single and multiple infections. Within the context of pri-
mary cervical screening, we considered samples to have a positive
CLART test result if the assay detected one or more of the 13 high-risk
HPV genotypes. All other infections detected by CLART were consid-
ered to represent negative, non-actionable, screening findings. In the
analysis, these infections could only contribute to multiple infections
in the presence of at least one high-risk genotype.
Women with abnormal cytology were managed according to rou-
tine Danish recommendations (Appendix). Women with cytology-nor-
mal/HPV-positive test results on one or more HPV assays were
invited, for study purposes, for repeated cytology and HPV testing in
18 months. All colposcopies were undertaken under routine condi-
tions either by a hospital or privately practicing gynaecologists. In
Denmark, it is recommended to take directed biopsies from all suspi-
cious areas after application of acetic acid, and a random biopsy from
all quadrants if lesions are not visible. The most severe follow-up test-
ing results in 2.5 years after the baseline were determined through
linkage to the national Danish Pathology Register (Patobank).29
2.2 | Statistical analysis
Samples with inadequate cytology (N=25, 0.5%) were excluded, as
were samples with invalid CLART test results (N=12, 0.2%). The
remaining 4997 samples were included in the analysis. They repre-
sent a typical collection of samples handled by a cytology laboratory
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during its routine operations. Their screening histories were deter-
mined from the Patobank from 1 January 2000 until the baseline
testing date. These screening histories were used to determine the
reason for taking each sample. The reasons were categorised as
either primary screening or follow-up of recent abnormalities (see
Appendix for detailed definitions). In the present analysis, we limited
the primary screening population to samples taken at age 30-
65 years (N=2846 out of 4997), as younger women are not consid-
ered for HPV-based primary screening. Approximately 96% of these
women had normal, and 4% had abnormal routine cytology. Previous
studies used various definitions for their referral populations. Typi-
cally, they included women with cytological abnormalities at any age
and regardless of their screening history, ranging from women with
single ASCUS samples to women attending colposcopy owing to
high-grade cytological abnormalities or several consecutive low-grade
screening-detected abnormalities. Our primary definition of a referral
population included all women with ≥ASCUS, so as not to exagger-
ate the differences between our referral and screening populations
(N=367 out of 4997, of which 127 were also included in the primary
screening population described above). We separately investigated
women with follow-up samples in the Horizon study showing normal
baseline cytology (N=516 out of 4997); samples from these women
are also readily available from routine pathology registrations and
are sometimes included among referral populations.
We calculated median signal strengths and their interquartile
ranges (IQR) for HC2, cobas and APTIMA. The dispersion of the signal
strength values was estimated by the range between IQR[1]/median
and IQR[3]/median. If more than one cobas’ channel returned a posi-
tive test result (18% of cobas-positive women with normal and 26%
with abnormal cytology), we considered the signal strength on the
most strongly positive channel (=the lowest Ct value). Signals closer to
the cut-off were considered to be weaker. Signal strength is not avail-
able for CLART, so signal strength statistics could not be determined.
Differences in median signal strengths of the detected HPV
infections and the detected ≥CIN2 lesions were assessed between
different populations using lognormal distribution. Lognormal distri-
bution was used for testing as it provided the best fit for the data.
P-values based on other distributions were very close to the
reported P-values based on the lognormal distribution. They were
adjusted for all known characteristics of the woman and/or the
study sample; see table footnotes for details specific to each com-
parison. We compared the following populations: (1) abnormal vs
normal cytology in all samples (N=4997), (2) abnormal vs normal
cytology in primary screening samples (N=2846), (3) primary screen-
ing samples (N=2864) vs referral population samples with abnormal
cytology (N=367) and (4) primary screening samples with normal
cytology (N=2719) vs referral population samples with normal cytol-
ogy (N=516). Analyses were performed with SAS Ver. 9.3 (SAS Insti-
tute, Cary, NC, USA).
Finally, we evaluated the differences in the assays’ ability to
detect HPV infections and ≥CIN2 by determining the degree of their
concordance in baseline testing results. As previously,2 concordance
was calculated as the conditional probability that all four assays
returned a positive test result if at least one of the four was positive,
and discordance as [100%-concordance]. The 95% confidence inter-
vals (CI) for relative discordance comparing the various populations
were calculated assuming lognormal distribution.
2.3 | Ethical approval
Baseline testing on the residual material was undertaken as a quality
development study and did, in line with the Danish regulation of
biomedical research, not require ethical approval. Ethical Committee
of the Danish Capital Region approved the follow-up of cytology-
normal/HPV-positive women (H-4-2012-120), and women signed
informed consent. The study was notified to the Danish Data
Inspection Agency (notification numbers 2010-41-5594 and AHH-
2015-080/I-Suite: 04109).
3 | RESULTS
3.1 | Sample description
Among all 4997 samples, 367 (7%) were associated with abnormal,
and 4630 (93%) with normal baseline cytology (Table 1). In total, 1660
(33%) samples showed HPV infections detected by one or more assays
and 175 (4%) were associated with HPV-positive ≥CIN2.
In primary screening at 30-65 years (N=2846), 127 (4%) samples
were associated with abnormal and 2719 (96%) with normal cytol-
ogy; 651 (23%) samples showed HPV infections and 50 (2%) were
associated with HPV-positive ≥CIN2.
3.2 | Signal strengths in detected HPV infections
A comparison of central tendency measures showed that signal
strengths, particularly for HC2, were not distributed normally
(Table 2).
Median signal strengths for positive HPV test results in all 4997
samples were weaker in normal than in abnormal cytology (Table 3).
For HC2, the median RLU/CO in normal cytology was 11.0 (IQR:
3.3-52.8), compared to 124.2 (IQR: 22.8-506.9, P≤.001) with abnor-
mal cytology. For cobas, the median Ct values were 33.5 (IQR: 29.6-
37.5) and 26.9 (IQR: 23.7-31.3, P≤.001), respectively, and for
APTIMA, the median S/CO values were 10.2 (IQR: 5.8-11.3) and
11.1 (IQR: 9.4-15.5, P≤.001), respectively.
For HC2, the ranges for IQR/median ratios were 0.3[IQR1]-4.8
[IQR3] for normal and 0.2[IQR1]-4.1[IQR3] for abnormal cytology;
for cobas, they were 0.9[IQR1]-1.1[IQR3] for normal and 0.9[IQR1]-
1.2[IQR3] for abnormal cytology; and for APTIMA, they were 0.6
[IQR1]-1.1[IQR3] for normal and 0.8[IQR1]-1.4[IQR3] for abnormal
cytology (not tabulated). This suggested that, in relative terms, HPV
signal strengths were approximately as heterogeneous for normal as
for abnormal cytology.
In primary screening, 558 (86%) of 651 samples with positive
HPV test results on one or more assays had normal, and 93 (14%)
had abnormal baseline cytology (Table 1/footnote). The patterns in
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signal strengths that were observed for all 4997 samples when com-
paring normal vs abnormal cytology (Table 3 above) were also seen
in primary screening, regardless of the assay (Table 3 below).
Next, we compared the complete screening population (N=2846;
of which 4% of samples were associated with abnormal cytology)
with the referral population with abnormal cytology (N=367). The
median signal strengths of HPV-positive samples were weaker in the
primary screening than in the referral population (P<.001; Table 4).
In the referral population with normal cytology (N=516), the
median signal strengths (Table 5) appeared similar to those in sam-
ples associated with normal cytology from primary screening
(N=2719; Table 3 below).
3.3 | Signal strengths in detected ≥CIN2
When considering all 4997 samples, HPV-positive ≥CIN2 with nor-
mal cytology had weaker median signal strengths than HPV-positive
≥CIN2 with abnormal cytology (P<.001 for HC2 and cobas, and
P<.002 for APTIMA; Table 3 above). For HC2, the median RLU/CO
was 25.6 (IQR: 8.6-67.2) in normal and 124.2 (IQR: 27.8-439.8,
P≤.001) in abnormal cytology. For cobas, the median Ct values were
30.4 (IQR: 27.9-32.9) and 26.8 (IQR: 23.9-30.9, P≤.001), respectively.
For APTIMA, the median S/CO values were 10.7 (IQR: 8.4-11.7) and
11.2 (IQR: 10.6-16.9, P≤.01), respectively.
The differences in HPV signal strengths between normal and abnor-
mal cytology associated with ≥CIN2 were also seen for samples from
primary screening but were significant only for APTIMA (P=.02; Table 3
below). The primary screening population as a whole (Table 4), where
the majority of ≥CIN2 in our population had abnormal cytology, also
showed weaker signal strengths than the referral population with
abnormal cytology, although the differences were not significant. Refer-
ral population samples with normal cytology (Table 5) were fairly similar
to primary screening samples with normal cytology (Table 3 below).
3.4 | Concordance between HPV assays in
detecting HPV infections and ≥CIN2
Among all 4997 samples, 1343 (29%) of 4630 samples with normal
cytology had a positive test result on one or more HPV assays, but
in 902 (67%) of the 1343 samples, the assays showed discordance
(Table 6). For samples with abnormal cytology, the assays were dis-
cordant in 84/317 (26%). Hence, the relative risk of discordance in
detecting HPV infections was significantly lower in abnormal com-
pared to normal cytology: 0.39 (0.26/0.67, 95% CI: 0.33-0.48). In
samples from primary screening (N=2846), the relative risk of assay
discordance in detecting HPV infections was 0.42 (95% CI: 0.31-
0.56) for abnormal vs normal cytology. The risk of assay discordance
TABLE 1 Age distribution, cytology test results, detected HPV
infections and HPV-positive ≥CIN2 lesions in all women and primary
screening at age 30-65 y
All women
(N=4997) (%)b
Primary screening
at age 30-65
(N=2846) (%)
Age (years)
<23 161 (3) –
23-29 1514 (30) –
30-65 3212 (64) 2846 (100)d
>65 110 (2) –
Cytology at baseline
Normal 4630 (93) 2719 (96)
Abnormal (≥ASCUS) 367 (7)c 127 (4)
Endpoints detected by ≥1 HPV assay
HPV infections 1660 (33) 651 (23)e
HPV-positive ≥CIN2a 175 (4) 50 (2)
ASCUS, atypical squamous cells of undetermined significance; CIN, cervi-
cal intraepithelial neoplasia; HPV, Human Papillomavirus.
aLesions positive on at least one of the four HPV assays. Two additional
cases of ≥CIN2 had a negative test result on all four HPV assays (one of
which in a woman with a primary screening sample at 30-65 y). As the
focus of this analysis was on ≥CIN2 detectable by HPV assays, these
two cases were not considered here.
bOf the 4997 women with consecutive, routine samples, 2846 (57%) had
primary screening samples at age 30-65 y, 1509 (30%) had primary
screening samples at other ages, and the remaining 642 (13%) women
had samples taken for follow-up of recent abnormalities. Of the 642
women with follow-up samples, 516 (80%) had normal cytology and the
remaining 126 (20%) had abnormal cytology. Of the 367 women with
abnormal cytology, 127 (35%) were from primary screening at age 30-
65 y, 114 (31%) from primary screening at other ages and the remaining
126 (34%) were from follow-up of recent abnormalities.
cThese women were described in detail by Rebolj et al.25
dThese women were described in detail by Rebolj et al.27 The present
analysis excluded women with inadequate cytology and/or an invalid
CLART test result at baseline.
eOf the 651 women with a positive HPV test result on at least one
assay, 558 (86%) had normal and 93 (14%) had abnormal cytology.
TABLE 2 Distribution of signal strengths in HPV-positive women, by population and HPV assay
All samples (N=4997) Primary screening at 30-65 y (N=2846)
HC2 cobas APTIMA HC2 cobas APTIMA
N testing positive (%) 1021 (20) 1343 (27) 837 (12) 335 (12) 464 (16) 270 (9)
Signal strengths in HPV-positive women
Range 1.0-3100.5 11.8-40.5 0.5-63.9 1.0-2818.9 12.2-40.4 0.5-31.8
Mean (SD) 166.7 (380.1) 32.0 (5.4) 10.3 (6.2) 135.5 (329.5) 32.9 (5.4) 9.4 (5.5)
Median (IQR) 19.5 (4.3-132.6) 32.4 (27.9-36.7) 10.6 (7.1-11.8) 13.5 (3.7-97.0) 33.8 (28.7-37.9) 10.1 (6.0-11.3)
HC2, Hybrid Capture 2; HPV, Human Papillomavirus; IQR, interquartile range; SD, standard deviation.
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in referral population samples with normal cytology (N=516) was
similar to that in cytologically normal screening samples (N=2719),
relative discordance: 0.92 (95% CI: 0.84-1.02; not tabulated).
Discordance between the four assays was less frequent in sam-
ples associated with ≥CIN2, 26% in normal and 15% in abnormal
cytology when all 4997 samples were included. In primary screening,
discordance was 33% in normal cytology and 11% in abnormal cytol-
ogy. Although assay discordance in detecting ≥CIN2 was two to
three times as frequent in normal than in abnormal cytology, the dif-
ference did not reach statistical significance in our data.
4 | CONCLUSIONS
In our study, HPV infections had weaker median signal strengths in
normal than in abnormal cytology. Being in the range of approximately
TABLE 3 Median signal strengths (IQR) of detected HPV infections and HPV-positive ≥CIN2, by HPV assay and cytology test result at
baseline
Baseline cytology result
HPV assay
HC2 cobas
CLART
APTIMA
Positive test
result (%)
Md signal
strength (IQR)
Positive test
result (%)
Md signal
strength (IQR)
Positive test
result (%)
Positive test
result (%)
Md signal
strength (IQR)
All women (N=4997)
HPV infections
Normal (N=4630) 721 (16) 11.0 (3.3-52.8) 1061 (23) 33.5 (29.6-37.5) 992 (21) 581 (13) 10.2 (5.8-11.3)
Abnormal (N=367) 300 (82) 124.2 (22.8-506.9) 282 (77) 26.9 (23.7-31.3) 269 (73) 256 (70) 11.1 (9.4-15.5)
Pa – <.001 – <.001 – – <.001
≥CIN2
Normal (N=57) 52 (91) 25.6 (8.6-67.2) 56 (98) 30.4 (27.9-32.9) 55 (96) 44 (77) 10.7 (8.4-11.7)
Abnormal (N=118) 114 (97) 124.2 (27.8-439.8) 113 (96) 26.8 (23.9-30.9) 112 (95) 106 (90) 11.2 (10.6-16.9)
Pa – <.001 – <.001 – – <.002
Primary screening at 30-65 y (N=2846)
HPV infections
Normal (N=2719) 249 (9) 9.4 (2.6-46.5) 385 (14) 34.5 (30.0-38.4) 377 (14) 199 (7) 9.2 (4.2-11.2)
Abnormal (N=127) 86 (68) 83.2 (10.0-330.7) 79 (62) 27.2 (25.2-33.0) 76 (60) 71 (56) 10.8 (9.6-12.9)
Pb – <.001 – <.001 – – <.001
≥CIN2
Normal (N=12) 9 (75) 24.9 (7.8-88.8) 12 (100) 32.1 (29.1-34.0) 12 (100) 9 (75) 10.7 (8.3-11.8)
Abnormal (N=38) 37 (97) 92.6 (31.8-264.8) 37 (97) 27.1 (24.8-33.5) 37 (97) 37 (97) 10.8 (10.4-11.5)
Pb – .08 – .10 – – .02
CIN, cervical intraepithelial neoplasia; HC2, Hybrid Capture 2; HPV, Human Papillomavirus; IQR, interquartile range; Md, median.
aAdjusted for age (<30 vs ≥30 y), reason for taking the sample (primary samples vs follow-up samples), type of infection (single vs multiple).
bAdjusted for type of infection (single vs multiple).
TABLE 4 Median signal strengths (IQR) for samples with detected HPV infections and HPV-positive ≥CIN2, by HPV assay and type of
population (primary screening vs referral population with abnormal cytology)
Population type
Detection of HPV infections, Md signal strength (IQR) Detection of ≥CIN2, Md signal strength (IQR)
HC2 cobas APTIMA HC2 cobas APTIMA
Primary screening at
30-65 y (N=2846)
13.5 (3.7-97.1) 33.8 (28.6-37.9) 10.1 (5.9-11.3) 75.7 (14.4-216.9) 28.1 (25.1-33.6) 10.8 (10.3-11.5)
Referral population
with abnormal
cytology (N=367)
124.2 (22.8-506.9) 26.9 (23.7-31.3) 11.1 (9.4-15.5) 124.2 (27.8-439.8) 26.8 (23.9-30.9) 11.2 (10.6-16.9)
Pa <.001 <.001 <.001 .54 .14 .17
CIN, cervical intraepithelial neoplasia; HC2, Hybrid Capture 2; HPV, Human Papillomavirus; IQR, interquartile range; Md, median.
Note: From the 367 women in the referral population with abnormal cytology (at any age), 317 (86%) were HPV-positive on at least one HPV assay,
and 118 (32%) had HPV-positive ≥CIN2.
aAdjusted for type of infection (multiple vs single).
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100 RLU/CO on HC2 and ca. 6 Ct on cobas, the absolute differences
in the median signal strengths were not trivial. Abnormal cytology
samples also showed a higher degree of assay concordance than nor-
mal cytology samples in detecting HPV infections.
HPV testing detects more ≥CIN2 than cytology.30 At least part
of ≥CIN2 in normal cytology is clinically important. In the two-round
screening data from randomised trials, treatment of cytology-nor-
mal/HPV-positive ≥CIN2 reduced the population’s risk of developing
cervical cancer.1 In our study, most ≥CIN2 were detected by all HPV
assays. Nonetheless, the lower median signal strengths and assay
discordance in women with normal cytology suggested that cytol-
ogy-normal ≥CIN2 are not only difficult to detect through cytology
but might also be more difficult to detect with HPV assays than is
the case with cytology-abnormal ≥CIN2.
HPV assays utilise various molecular targets and methodologies,
which result in different test dynamics. Differences in assay character-
istics and calibration may, as discussed previously,2 explain why the
assays return discordant HPV test results. Higher amounts of the tar-
get viral input in a sample and the associated stronger signals may,
however, make all assays more likely to return a positive test result.
We observed this pattern in women with cytological and histological
abnormalities, who, in turn, also showed a higher likelihood of concor-
dance between HPV assays than women without abnormalities.
Based on these data, we can infer that referral population stud-
ies focusing predominantly on women with abnormal cytology
underestimate the differences between HPV assays that would
become apparent in primary screening. With a view on the practi-
cality of undertaking the necessary assay validation studies, an
international expert group has developed non-inferiority testing
guidelines for primary screening. These guidelines require that new
assays be compared to HC2.31 They call for the use of a relatively
small number of samples from population-based cohorts screened
and managed according to HC2 and cytology test results. Even
although this is not always followed in research practice, our data
support the guidelines’ requirement to include samples from true
primary screening populations with a representative distribution of
normal and abnormal cytology. However, if primary screening
cohorts are not available for study, our data suggest that including
a representative proportion of normal-cytology samples taken for
follow-up of recent abnormalities might offer a reasonable shortcut.
In our study, these samples had fairly similar signal strengths as nor-
mal-cytology primary screening samples and showed similar assay
discordance. Nevertheless, the use of normal-cytology follow-up
samples as a substitute for normal-cytology screening samples
needs further validation.
The strength of our data was that samples taken for different
reasons originated from the same population. All cytology was read
by the same laboratory under routine conditions, which were not
influenced by the study. Moreover, unlike in some other split-sample
studies evaluating several HPV assays,10 cytology-normal/HPV-posi-
tive women were invited for repeated testing. Approximately 60% of
these women had a follow-up, regardless of the assay that detected
the HPV infection.27 This proportion was consistent with the data
from randomised controlled trials comparing HPV testing to cytology
in primary cervical screening.32 Finally, management according to
TABLE 5 Median signal strengths (IQR) for samples with detected
HPV infections and HPV-positive ≥CIN2 in 516 women from a
referral population with normal cytology, ie, undergoing follow-up
testing for a recent abnormality and current samples showing normal
cytology, by HPV assay
Md signal
strength (IQR)
Detected HPV infections
HC2 8.5 (2.7-40.9)
Cobas 34.5 (30.3-37.8)
APTIMA 10.5 (6.5-11.2)
Detected ≥CIN2
HC2 9.6 (4.6-68.0)
Cobas 33.0 (27.8-33.4)
APTIMA 10.3 (3.5-10.8)
CIN, cervical intraepithelial neoplasia; HC2, Hybrid Capture 2; HPV,
Human Papillomavirus; IQR, interquartile range; Md, median.
Note: In the Horizon study, there were in total 516 women with normal
cytology in samples taken for follow-up of a recent abnormality. Of
these, 200 (39%) had a positive test result on at least one HPV assay,
and 10 (2%) had HPV-positive ≥CIN2.
TABLE 6 Discordance between HPV assays, by cytology test result
Endpoint
All women (N=4997) Women with primary screening samples, 30-65 y (N=2846)
Abnormal cytology
(N=367)
Normal cytology
(N=4630)
RD (95% CI) for
abnormal vs
normal cytology
Abnormal cytology
(N=127)
Normal cytology
(N=2719)
RD (95% CI) for
abnormal vs
normal cytology
Positive
on ≥1
assay
Positive
on <4
assays
Positive
on ≥1
assay
Positive
on <4
assays
Positive
on ≥1
assay
Positive
on <4
assays
Positive
on ≥1
assay
Positive
on <4
assays
HPV infections 317 84 (26%) 1343 902 (67%) 0.39 (0.33-0.48) 93 30 (32%) 558 433 (78%) 0.42 (0.31-0.56)
≥CIN2 118 18 (15%) 57 15 (26%) 0.58 (0.32-1.06) 38 4 (11%) 12 4 (33%) 0.32 (0.09-1.07)
CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, Human Papillomavirus; RD, relative discordance.
Note: In women with normal cytology undergoing follow-up for a recent abnormality (N=516), 200 (39%) tested positive on at least one HPV assay. Of
the 200 women, 143 (72%) did not test positive on all four assays. The concordance between the four assays in detecting HPV infections was similar
as in women with normal cytology undergoing primary screening, relative discordance for normal cytology in follow-up vs primary screening: 0.92 (95%
CI: 0.84-1.02).
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HPV status was not limited to the results of a single assay, as
women qualified for repeated testing if one or more HPV assays
were positive. This allowed for a more comprehensive evaluation of
the differences in detecting HPV-related abnormalities between the
four assays than has been the case in several previous studies.
Nevertheless, this is a post-hoc analysis, and the study was not
powered to detect differences between cytology-normal and cytol-
ogy-abnormal CIN. In primary screening, only 12 out of 50 ≥CIN2
were associated with normal cytology. With larger numbers of
screened women, the observed differences in the ability of the
assays to detect ≥CIN2 could, plausibly, reach statistical significance.
Studies from other populations are warranted to corroborate our
findings.
In conclusion, differences between HPV assays tend to be under-
estimated when studied only in women with abnormal cytology.
Therefore, experiences and conclusions drawn from studies without
a representative sample of women with normal cytology should be
only cautiously used as evidence for the use of new HPV assays in
primary cervical screening.
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APPENDIX
FOLLOW-UP RECOMMENDATIONS FOR WOMEN WITH
CYTOLOGICAL ABNORMALITIES
As the study was nested into routine screening, women with cyto-
logical abnormalities were managed according to the routine recom-
mendations valid at the time of the study. The study did not affect
these processes. An immediate referral for colposcopy was recom-
mended to women with high-grade squamous intraepithelial lesions
(HSIL) or worse, atypical glandular cells, atypical squamous cells—
cannot exclude HSIL and HC2-positive ASCUS at age ≥30 years.
Other women with ASCUS and women with low-grade squamous
intraepithelial lesions (LSIL) were recommended for repeated cytol-
ogy-based testing. At follow-up testing, they were referred for col-
poscopy in case of repeated abnormalities. Among women
undergoing primary screening at age 30-65 years, 92% had follow-
up in 2.5 years after the baseline testing.25
FOLLOW-UP RECOMMENDATIONS FOR CYTOLOGY-
NORMAL/HPV-POSITIVE WOMEN
At the time of the study, HPV-based primary screening was not rec-
ommended in Denmark, and cytology-normal/HPV-positive women
had to be invited for follow-up for research purposes. Women were
invited for repeated cytology and HPV testing in approximately
18 months after the baseline testing, independent of which HPV
assay(s) detected their infection. At follow-up, women were recom-
mended for colposcopy if they had ≥ASCUS or a positive HC2 test
result. The ethical committee of the Capital Region approved of this
follow-up and women provided written informed consent. As the
study was nested into routine practice, women may have also had
follow-up other than study testing. Combined, approximately 60% of
the women had follow-up in 2.5 years after the baseline testing.27
DEFINITION OF PRIMARY SCREENING SAMPLES
In the Patobank,29 the reason for taking the sample is not registered
systematically. We used an algorithm to determine which samples
were most likely taken for primary screening, ie, not for follow-up of a
recent abnormality. Primary samples were defined as those without a:
• previous histological diagnosis of cervical cancer,
• histologically-confirmed cervical intraepithelial neoplasia (CIN) of
any grade in ≤3 years,
• ASCUS cytology or non-CIN cervical histology in ≤15 months,
• more severe cytological abnormality, inadequate cytology or a
positive HPV test result in ≤12 months.
Reflecting routine practice, primary samples included a small pro-
portion of samples taken for investigation of symptoms. The Pato-
bank data were retrieved from 1 January 2000 onwards.
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Registration of cervical cytology and histology in the Patobank
became nationally complete only gradually. Most screening samples
are taken by privately practicing general practitioners, whereas pri-
vate gynaecology practices are available particularly in the more
urbanised areas. Cytology and histology samples can be read by
pathologists working in hospital laboratories (where the registration
in the Patobank has been complete since 1997)29 and by privately
practicing pathologists. Registration of samples in the national Pato-
bank is now mandatory also for private pathologists, although the
year in which this was implemented depended on the geographical
area. Since 1990, cervical screening and histology samples taken by,
or evaluated by privately practicing specialists, have also been regis-
tered in the National Health Service Register.33 As this is a reim-
bursement register, it is considered highly complete but does not
contain diagnostic information. For each woman, and for cytology
separately from histology, we compared the numbers of registered
cervical samples in the Patobank and the National Health Service
Register until the end of 2010. All duplicates were excluded. We
defined the start of (reasonably) complete registration in the Pato-
bank as the year in which it started to include at least 85% of all
samples. For cervical cytology, this analysis suggested that for the
period 2000-2010, approximately 7% of all samples were not regis-
tered in the Patobank; this was 11% for cervical histology. Neverthe-
less, Copenhagen County had highly incomplete registration of
cytology before 2005, and Sønderjylland County before 2001. Our
threshold for considering the registration reasonably complete was
reached for histology in Frederiksberg Municipality in 2001, Sønder-
jylland and Frederiksborg Counties in 2003, Storstrøm County in
2006, and Copenhagen County in 2009. The remaining counties
reached the threshold before 2000.
Women from (1) Copenhagen Municipality and (2) Frederiksberg
Municipality, the catchment areas of our laboratory at the time of
the study, have had highly complete registration of cytology since (1)
1991 and (2) 1993, and highly complete registration of histology
since (1) 1998 and (2) 2001. Incomplete registration elsewhere in
Denmark will affect our analyses; however, the impact was most
likely limited as migration to the two municipalities from elsewhere
in Denmark was infrequent for women aged 30-65 years (estimated
at <3% for the year 2005).34
HPV TESTING PROTOCOLS IN THE HORIZON STUDY
Processing of samples and assay instrumentation
The study protocol, sample storage, and assay testing protocols were
agreed upon with all manufacturers before the study. All instrumen-
tation and software were used as supplied and maintained by the
manufacturers.
Baseline
These testing protocols were published, with minor textual revisions,
previously.2
HC2
We used cytology post-quot material that remained from the cytol-
ogy procedure. As part of the cytology processing, post-quot mate-
rial was diluted approximately 1:1 in SurePath. DNA was either
denatured prior to testing by pre-treating manually in line with the
manufacturer’s CE-IVD protocol, or was isolated and purified using
the DSP AXpH DNA kit on QIASymphony SP (Qiagen, Hilden, Ger-
many). Testing was undertaken on automated Rapid Capture System
(RCS; Qiagen, Gaithersburg, MD, USA). A minority of samples used
for routine HC2 triage of women with ASCUS at age ≥30 years were
denatured and tested manually.
Cobas
1 mL of the diluted material was aliquoted into a 13 mL round bot-
tom test tube (Sarstedt, cat. no NC9018280), stored at 2-8°C until
testing. No pre-treatment of SurePath samples was required. Extrac-
tion of DNA was undertaken on cobas 9480, and amplification and
detection of high-risk HPV DNA on cobas z480 analyser. Fluores-
cent TaqMan probes were used for detection of the amplicons dur-
ing polymerase chain reaction (PCR) cycles. Amplification and
detection of the 330-bp b-globin was used as an internal control of
the testing processes.
CLART
1 mL of the diluted SurePath sample was spun down for 5 minutes
at 14 000 revolutions per minute, with supernatant removed and cell
pellet re-suspended in a mix of 180 lL phosphate buffered saline
(109 conc. pH 7.4, Pharmacy product) and 20 lL Proteinase K (re-
combinant, PCR Grade, Roche Diagnostics, Rotkreuz, Switzerland).
Samples were then vortexed and incubated for 1 hour at 56°C and
1 hour at 90°C. HPV DNA was purified using MagNa Pure LC 96
and MagNA Pure LC 32 instruments (Roche Diagnostics) with
MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics).
PCR amplification was performed using the CLART HPV2 Amplifica-
tion kit (Genomica). 5 lL of purified DNA were used for the PCR
amplification. Prior to visualisation, the PCR products were dena-
tured at 95°C for 10 minutes. Visualisation was performed using
10 lL of the denatured PCR products on the CLART microarray.
Hybridisation between the amplicons and their specific probes on
the microarray resulted in formation of an insoluble precipitate of
peroxidase when adding a Streptavidin conjugate that binds to the
biotin-labeled PCR products. The precipitate was analyzed automati-
cally on the Clinical Array Reader (Genomica).
APTIMA
1 mL of the diluted sample was aliquoted into an APTIMA Specimen
Transfer Tube containing 2.9 mL of buffered solution (Hologic/Gen-
Probe). Samples were treated with proteinase K prior to testing,
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using the Pace 2 Fast Expression Kit containing 1 mL diluent and
lyophilised reagent (all from Hologic/Gen-Probe). 100 lL of the
reconstituted proteinase K was added to each Specimen Transfer
Tube and incubated at 65°C for 2 hours. The treated specimen tube
was stored at 2-8°C until testing. Testing was performed on the
PANTHER platform.
Follow-up testing for women with cytology-normal/
HPV-positive test results at baseline
Testing on HC2 for all follow-up samples was performed on the
cytology post-quot material with manual DNA denaturation followed
by testing on the RCS.
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